Korean biopharmaceutical company CanariaBio Inc announced on Friday that it has completed enrolment in a Phase 2 clinical trial evaluating oregovomab, an immunotherapy drug, in combination with chemotherapy (paclitaxel and carboplatin) for advanced ovarian cancer.

The study, known as FLORA-6, will assess the efficacy and safety of the treatment regimen in patients with newly diagnosed advanced epithelial ovarian cancer.

Oregovomab is a monoclonal antibody targeting CA 125, a biomarker commonly found in ovarian cancer. This immunotherapy drug has the potential to address the challenges of treatment resistance and limited efficacy in ovarian cancer therapy.